FERRING STATEMENT ON THE IMPACT OF COVID-19 PANDEMIC ON PRODUCT AND SUPPLY

As the global COVID-19 pandemic rapidly evolves, Ferring continues to monitor developments closely and remains committed to adhering to measures put forward by health authorities at the global, national and local levels to limit the spread of infection.

Our thoughts are with the people and families affected by COVID-19 around the world, including our patients and those working tirelessly to address this pandemic.

In addition to policies that protect the health of our employees and prevent the spread of infection, Ferring has put in place comprehensive mitigation plans to limit disruption in manufacturing and ensure continuity of supply of our products to healthcare providers and patients around the world. Ferring continues to manufacture and test its products in accordance with US FDA and local regulatory body approved processes and procedures to assure our products meet all standards and criteria.

Ferring encourages patients with questions about their condition or treatment, to contact their healthcare providers for specific guidance in managing their individualized therapies and treatment plans, during the current healthcare situation.

For medical questions regarding Ferring products, please contact Ferring Medical Information team at: 1-888-FERRING (1-888-337-7464; option #2) or email us at MedQueriesUS@ferring.com.

If you are a healthcare professional, distributor or wholesaler and have supply questions regarding Ferring products, please contact our Customer Service team at 1-888-FERRING (1-888-337-7464; option #1).

US-CORP-2000024

This site contains material about Ferring Pharmaceuticals Inc. (hereinafter "Ferring") and its various products that may be of interest to Ferring's employees and customers, as well as to members of the health care community and the general public. Please feel free to browse this web site. Your access and use of the information contained herein is subject to the following terms and conditions and all applicable laws. By accessing and browsing this web site, you accept, without limitation or qualification, these terms and conditions and acknowledge that they supersede any other agreement between you and Ferring.

All information on this site is intended for US audiences only.

CERVIDIL, CLENPIQ, ENDOMETRIN, EUFLEXXA, FIRMAGON, MENOPUR, NOCDURNA, NOVAREL, and ZOMACTON are registered trademarks of Ferring B.V. INVOCELL is a registered trademark of INVO BioScience. ORTIKOS is a trademark of Sun Pharma Global FZE.

©2008-2020 Ferring Pharmaceuticals.  US-CORP-2000045